Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (105) 105
life sciences & biomedicine (99) 99
humans (68) 68
melanoma (54) 54
oncology (52) 52
female (45) 45
male (44) 44
middle aged (39) 39
aged (34) 34
dermatology (32) 32
immunotherapy (32) 32
adult (28) 28
ipilimumab (23) 23
melanoma - drug therapy (21) 21
metastasis (20) 20
aged, 80 and over (19) 19
human necessities (19) 19
hygiene (19) 19
immunology (19) 19
medical or veterinary science (19) 19
preparations for medical, dental, or toilet purposes (19) 19
cancer (18) 18
pembrolizumab (18) 18
biological and medical sciences (17) 17
care and treatment (17) 17
skin cancer (16) 16
animals (15) 15
medical sciences (15) 15
microbiology (15) 15
nivolumab (15) 15
patients (15) 15
melanoma - pathology (14) 14
skin (14) 14
skin neoplasms - drug therapy (14) 14
biochemistry (13) 13
chemistry (13) 13
immune checkpoint (13) 13
retrospective studies (13) 13
treatment outcome (13) 13
analysis (12) 12
medicine, research & experimental (12) 12
metastases (12) 12
myocarditis (12) 12
research & experimental medicine (12) 12
antibodies, monoclonal - therapeutic use (11) 11
antineoplastic agents - adverse effects (11) 11
beer (11) 11
cell death (11) 11
compositions thereof (11) 11
culture media (11) 11
enzymology (11) 11
melanoma - therapy (11) 11
metallurgy (11) 11
microorganisms or enzymes (11) 11
mutation or genetic engineering (11) 11
propagating, preserving or maintaining microorganisms (11) 11
specific therapeutic activity of chemical compounds ormedicinal preparations (11) 11
spirits (11) 11
vinegar (11) 11
wine (11) 11
abridged index medicus (10) 10
antibodies, monoclonal - adverse effects (10) 10
complications and side effects (10) 10
antineoplastic agents (9) 9
antineoplastic agents - therapeutic use (9) 9
immunotherapy - methods (9) 9
medical prognosis (9) 9
mice (9) 9
research article (9) 9
risk factors (9) 9
skin neoplasms - pathology (9) 9
tumors (9) 9
young adult (9) 9
cancer therapies (8) 8
clinical trials (8) 8
inhibitors (8) 8
interleukin-12 - genetics (8) 8
medizinische fakultät (8) 8
melanoma - secondary (8) 8
prognosis (8) 8
adolescent (7) 7
biomarker (7) 7
cytotoxicity (7) 7
hematology, oncology and palliative medicine (7) 7
medicine (7) 7
melanoma - mortality (7) 7
neoplasm metastasis (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
radiation (7) 7
research (7) 7
survival (7) 7
usage (7) 7
610 medicine & health (6) 6
apoptosis (6) 6
braf (6) 6
cell biology (6) 6
immune checkpoint inhibitors (6) 6
internal medicine (6) 6
lymphocytes (6) 6
melanoma - diagnosis (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text In Reply
by Heinzerling, Lucie
Deutsches Ärzteblatt international, ISSN 1866-0452, 05/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text In Reply
by Heinzerling, Lucie
Deutsches Ärzteblatt international, 05/2019, Volume 116, Issue 20, p. 363
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Braf inhibitors and radiation do not act synergistically to inhibit WT and V600E BRAF human melanoma
by Walter, Lisa and Heinzerling, Lucie
Anticancer research, ISSN 0250-7005, 03/2018, Volume 38, Issue 3, pp. 1335 - 1341
Vemurafenib | V600E mutant BRAF | Melanoma | Dabrafenib | BRAF inhibitor | BRAF | Radiotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Biotechnology | Ionizing radiation | Inhibitors | Radiosensitization | Cell survival | Cell death | Test procedures | Tumor cell lines | Survival | Necrosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
by Mahmood, Syed S and Fradley, Michael G and Cohen, Justine V and Nohria, Anju and Reynolds, Kerry L and Heinzerling, Lucie M and Sullivan, Ryan J and Damrongwatanasuk, Rongras and Chen, Carol L and Gupta, Dipti and Kirchberger, Michael C and Awadalla, Magid and Hassan, Malek Z.O and Moslehi, Javid J and Shah, Sachin P and Ganatra, Sarju and Thavendiranathan, Paaladinesh and Lawrence, Donald P and Groarke, John D and Neilan, Tomas G
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 16, pp. 1755 - 1764
pembrolizumab | cardio-oncology | nivolumab | myocarditis | ipilimumab | checkpoint inhibitor | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Glucocorticoids - therapeutic use | Myocarditis - chemically induced | Methylprednisolone - therapeutic use | Myocarditis - complications | Humans | Middle Aged | Myocarditis - drug therapy | Male | Myocarditis - blood | Case-Control Studies | Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Troponin T - blood | Female | Registries | Aged | Heart | Statistical analysis | Toxicity | Diabetes mellitus | Melanoma | Medical records | Cancer therapies | Patients | Regulatory approval | Troponin T | Confidence intervals | Myocarditis | Side effects | Troponin | Inhibitors | Immune checkpoint | Calcium-binding protein | Blood pressure | Heart diseases | Steroid hormones | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
by Fleschutz, Kathrin and Walter, Lisa and Leistner, Rumo and Heinzerling, Lucie
Anticancer research, ISSN 0250-7005, 09/2020, Volume 40, Issue 9, pp. 4937 - 4946
Life Sciences & Biomedicine | Oncology | Science & Technology | Phosphorylation | Cell survival | Small cell lung carcinoma | Lung cancer | Radiation | Non-small cell lung carcinoma | Radiation therapy | Kinases | Lymphoma | Synergistic effects | Radiosensitization | Inhibitors | Cell death | Cell cycle | Irradiation | Combined treatment | Protein-tyrosine kinase | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
by Gutzmer, Ralf and Koop, Anika and Meier, Friedegund and Hassel, Jessica C and Terheyden, Patrick and Zimmer, Lisa and Heinzerling, Lucie and Ugurel, Selma and Pföhler, Claudia and Gesierich, Anja and Livingstone, Elisabeth and Satzger, Imke and Kähler, Katharina C and for the German Dermatooncology Group (DeCOG) and German Dermatooncology Group DeCOG and German Dermatooncology Group (DeCOG)
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 75, pp. 24 - 32
Hematology, Oncology and Palliative Medicine | Autoimmunity | Metastatic melanoma | Pembrolizumab | Immune-related adverse events | Nivolumab | Ipilimumab | PD-1 inhibitor | Life Sciences & Biomedicine | Oncology | Science & Technology | Melanoma - complications | Recurrence | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Autoimmunity - immunology | Adult | Female | Retrospective Studies | Autoimmune Diseases - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Autoimmune Diseases - complications | Skin Neoplasms - complications | Melanoma - immunology | Melanoma - drug therapy | Aged | Autoimmune Diseases - chemically induced | Autoimmunity - drug effects | Medical colleges | Care and treatment | Melanoma | Biochemistry | Skin | Metastasis | Skin cancer | Apoptosis | Medical research | Therapy | PD-1 protein | Disorders | Clinical trials | Patients | Immunosuppressive agents | Metastases | Inhibitors | Cell death | Colitis | Autoimmune diseases | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text C-reactive protein as an early marker of immune-related adverse events
by Abolhassani, Amir-Reza and Schuler, Gerold and Kirchberger, Michael Constantin and Heinzerling, Lucie
Journal of cancer research and clinical oncology, ISSN 0171-5216, 10/2019, Volume 145, Issue 10, pp. 2625 - 2631
C-reactive protein | Medicine & Public Health | Hematology | Adverse events | Melanoma | Oncology | Cancer Research | Internal Medicine | Immune checkpoint inhibitors | Life Sciences & Biomedicine | Science & Technology | Proteins | Complications and side effects | Medical research | Analysis | Communicable diseases | Medicine, Experimental | Development and progression | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
by Moreira, Alvaro and Leisgang, Waltraud and Schuler, Gerold and Heinzerling, Lucie
Immunotherapy, ISSN 1750-743X, 01/2017, Volume 9, Issue 2, pp. 115 - 121
eosinophils | melanoma | biomarker | prognosis | immunotherapy | blood eosinophilia | Life Sciences & Biomedicine | Immunology | Science & Technology | Immunotherapy - methods | Melanoma - diagnosis | Prognosis | Cell Count | Humans | Middle Aged | Male | Biomarkers, Tumor | Young Adult | Neoplasm Metastasis | Animals | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Eosinophils - pathology | Melanoma - therapy | Melanoma - mortality | Antigens | Immunization | Statistical analysis | Cell survival | Cytokines | Leukocytes (eosinophilic) | Melanoma | Cytotoxicity | Vaccines | Metastasis | Cancer therapies | Eosinophilia | Metastases | Skin cancer | Pembrolizumab | Immune checkpoint | Lymphocytes | Immunotherapy | Medical prognosis | Peripheral blood | Biomarkers | Hypoxia | Hodgkin's disease | Tumors
Journal Article
Details down arrow
9. Full Text Senescence markers: Predictive for response to checkpoint inhibitors
by Moreira, Alvaro and Gross, Stefanie and Kirchberger, Michael Constantin and Erdmann, Michael and Schuler, Gerold and Heinzerling, Lucie
International journal of cancer, ISSN 0020-7136, 03/2019, Volume 144, Issue 5, pp. 1147 - 1150
melanoma | immunosenescence | immune checkpoint inhibitors | biomarker | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumor Necrosis Factor Receptor Superfamily, Member 7 - immunology | Flow Cytometry - methods | CD57 Antigens - immunology | Humans | Middle Aged | Male | CD28 Antigens - immunology | Biomarkers, Tumor | Lymphocytes - immunology | Melanoma - immunology | Aged, 80 and over | Female | Immunosenescence - immunology | Aged | Hepatitis A Virus Cellular Receptor 2 - immunology | CD57 antigen | CD27 antigen | Flow cytometry | Therapy | Phenotypes | Senescence | Leukemia | Lung cancer | Melanoma | Lymphocytes T | CD28 antigen | Patients | Metastases | Inhibitors | Immune checkpoint | Lymphocytes | Correlation analysis | Phenotyping | Peripheral blood | Biomarkers | Immunosenescence | Surface markers | Immune system | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Current Melanoma Treatments: Where Do We Stand?
by Moreira, Alvaro and Heinzerling, Lucie and Bhardwaj, Nina and Friedlander, Philip
Cancers, ISSN 2072-6694, 01/2021, Volume 13, Issue 2, p. 221
Brain research | Immune checkpoint | Medical prognosis | Immunotherapy | Melanoma | Clinical trials | Metastasis | FDA approval | Drug development | Patients | Survival | Metastases | melanoma | neoadjuvant | clinical trials | metastatic | adjuvant | resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma
by Kirchberger, Michael C and Hauschild, Axel and Schuler, Gerold and Heinzerling, Lucie
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 65, pp. 182 - 184
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Anti-PD-1 | Combined immunotherapy | Ipilimumab | Melanoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Immunotherapy - methods | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Antineoplastic Agents - therapeutic use | Drug Therapy, Combination - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Aged, 80 and over | Female | Aged | Complications and side effects | Metastasis | Analysis | Immunotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
by Moreira, Alvaro and Loquai, Carmen and Pföhler, Claudia and Kähler, Katharina C and Knauss, Samuel and Heppt, Markus V and Gutzmer, Ralf and Dimitriou, Florentia and Meier, Friedegund and Mitzel-Rink, Heidrun and Schuler, Gerold and Terheyden, Patrick and Thoms, Kai-Martin and Türk, Matthias and Dummer, Reinhard and Zimmer, Lisa and Schröder, Rolf and Heinzerling, Lucie
European journal of cancer (1990), ISSN 0959-8049, 01/2019, Volume 106, pp. 12 - 23
Neuromuscular side effects | Myositis | Immune checkpoint inhibitors | Tocilizumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Myositis - chemically induced | Myositis - immunology | Myositis - therapy | Young Adult | Neoplasm Metastasis | Time Factors | Aged, 80 and over | Adult | Female | Registries | Retrospective Studies | Neuromuscular Diseases - diagnosis | Databases, Factual | Neuromuscular Diseases - immunology | Skin Neoplasms - pathology | Molecular Targeted Therapy - adverse effects | Neuromuscular Diseases - chemically induced | Risk Assessment | Skin Neoplasms - immunology | Risk Factors | Myositis - diagnosis | Switzerland | Neuromuscular Diseases - therapy | Antineoplastic Agents, Immunological - adverse effects | Aged | Germany | Complications and side effects | Creatine | Skin cancer | Therapy | PD-1 protein | Creatine kinase | Clinical trials | Antibodies | Metastases | Proteins | Pembrolizumab | Myasthenia gravis | Immunotherapy | Heart diseases | Movement disorders | Neuromuscular diseases | Complications | Patients | Myocarditis | Side effects | Inhibitors | Immune checkpoint | Cell death | Polymyalgia rheumatica | Neuromuscular junctions | Muscle function | Skin | Myasthenia | Steroid hormones | Steroids | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
by Zimmer, Lisa and Apuri, Susmitha and Eroglu, Zeynep and Kottschade, Lisa A and Forschner, Andrea and Gutzmer, Ralf and Schlaak, Max and Heinzerling, Lucie and Krackhardt, Angela M and Loquai, Carmen and Markovic, Svetomir N and Joseph, Richard W and Markey, Kelly and Utikal, Jochen S and Weishaupt, Carsten and Goldinger, Simone M and Sondak, Vernon K and Zager, Jonathan S and Schadendorf, Dirk and Khushalani, Nikhil I
European journal of cancer (1990), ISSN 0959-8049, 2017, Volume 75, pp. 47 - 55
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Anti-PD-1 | Nivolumab | Ipilimumab | Melanoma | Disease progression | Treatment failure | Efficacy | Ipilimumab and nivolumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Disease Progression | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Skin Neoplasms - mortality | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Melanoma - mortality | Antimitotic agents | Medical colleges | Care and treatment | Cell death | Development and progression | Skin | Antineoplastic agents | Cancer | Therapy | PD-1 protein | Medical prognosis | Disease control | Patients | Survival | Apoptosis | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
by Bürkel, Felix and Jost, Tina and Hecht, Markus and Heinzerling, Lucie and Fietkau, Rainer and Distel, Luitpold
International journal of molecular sciences, ISSN 1661-6596, 12/2020, Volume 21, Issue 23, p. 9321
TOR protein | Flow cytometry | Biotechnology | Cell culture | Homologous recombination | DNA damage | Lung cancer | Clinical trials | Cytotoxicity | Homology | Metastasis | Kinases | DNA repair | Cancer therapies | Necrosis | Ewings sarcoma | Metastases | Skin cancer | Proteins | Cell cycle | Fibroblasts | Drug dosages | Deoxyribonucleic acid--DNA | Cell survival | Melanoma | I.R. radiation | Rapamycin | Radiation therapy | Gene expression | Double-strand break repair | Patients | Lymphoma | DNA-dependent protein kinase | Cell death | Cell lines | Immunofluorescence | Prostate cancer | Apoptosis | Index Medicus | mTOR | melanoma | DNA-PK | non-homologous end-joining (NHEJ) | radiosensitivity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
by Heppt, Markus V and Heinzerling, Lucie and Kähler, Katharina C and Forschner, Andrea and Kirchberger, Michael C and Loquai, Carmen and Meissner, Markus and Meier, Friedegund and Terheyden, Patrick and Schell, Beatrice and Herbst, Rudolf and Göppner, Daniela and Kiecker, Felix and Rafei-Shamsabadi, David and Haferkamp, Sebastian and Huber, Margit A and Utikal, Jochen and Ziemer, Mirjana and Bumeder, Irmgard and Pfeiffer, Christiane and Schäd, Susanne G and Schmid-Tannwald, Christoph and Tietze, Julia K and Eigentler, Thomas K and Berking, Carola
European journal of cancer (1990), ISSN 0959-8049, 09/2017, Volume 82, pp. 56 - 65
Uveal melanoma | Pembrolizumab | Biomarker | Immune checkpoint blockade | Ipilimumab | Nivolumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunotherapy - methods | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Uveal Neoplasms - secondary | Adult | Female | Retrospective Studies | C-Reactive Protein - analysis | Antibodies, Monoclonal, Humanized - therapeutic use | Biomarkers, Tumor - analysis | Proportional Hazards Models | Melanoma - secondary | Uveal Neoplasms - drug therapy | Regression Analysis | L-Lactate Dehydrogenase - blood | Melanoma - drug therapy | Survival Analysis | Aged | CTLA-4 Antigen - antagonists & inhibitors | Eosinophils - cytology | Antigens | Metastasis | Lymphocytes | Melanoma | Apoptosis | C-reactive protein | PD-1 protein | Cytotoxicity | Lymphocytes T | Malignancy | Multivariate analysis | Parameter identification | Blood | Risk factors | Skin cancer | Metastases | Proteins | CTLA-4 protein | Immunotherapy | Inhibition | Mortality | Health risks | Lactate dehydrogenase | Regression analysis | Risk analysis | Patients | Survival | L-Lactate dehydrogenase | Serum levels | Inhibitors | Immune checkpoint | Cell death | Medical prognosis | Monoclonal antibodies | Skin | Lactic acid | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights